Polio immunization policy in Mexico: economic assessment of current practice and future alternatives

Mascareñas, Abiel; Salinas, José Alberto; Tasset-Tisseau, A; Mascareñas, César; Khan, M. Mahmud

doi:10.1016/j.puhe.2004.08.020

Cited by 14 publications

(8 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An earlier study in Mexico examined the impact of moving from OPV to IPV vaccination schedule. The authors found that changing from the existing OPV-based routine schedule and intensive supplementary activities to a sequential IPV-OPV routine schedule using a pentavalent and IPV/OPV vaccines would save US$ 14.52 per vaccinated child, and changing to a full IPV routine schedule would save US$ 9.41 per vaccinated child [40]. This latter figure is consistent with the outcomes reported in Scenario 4 of our analysis using the lower price for the hexavalent vaccine.…”

Section: Discussionsupporting

confidence: 82%

Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine

Olivera¹,

Grau²,

Dibarboure

et al. 2020

BMC Health Serv Res

View full text Add to dashboard Cite

Background: The phased withdrawal of oral polio vaccine (OPV) and the introduction of inactivated poliovirus vaccine (IPV) is central to the polio 'end-game' strategy. Methods: We analyzed the cost implications in Chile of a switch from the vaccination scheme consisting of a pentavalent vaccine with whole-cell pertussis component (wP) plus IPV/OPV vaccines to a scheme with a hexavalent vaccine with acellular pertussis component (aP) and IPV (Hexaxim®) from a societal perspective. Cost data were collected from a variety of sources including national estimates and previous vaccine studies. All costs were expressed in 2017 prices (US$ 1.00 = $Ch 666.26). Results: The overall costs associated with the vaccination scheme (4 doses of pentavalent vaccine plus 1 dose IPV and 3 doses OPV) from a societal perspective was estimated to be US$ 12.70 million, of which US$ 8.84 million were associated with the management of adverse events related to wP. In comparison, the cost associated with the 4-dose scheme with a hexavalent vaccine (based upon the PAHO reference price) was US$ 19.76 million. The cost of switching to the hexavalent vaccine would be an additional US$ 6.45 million. Overall, depending on the scenario, the costs of switching to the hexavalent scheme would range from an additional US$ 2.62 million to US$ 6.45 million compared with the current vaccination scheme. Conclusions: The switch to the hexavalent vaccine schedule in Chile would lead to additional acquisition costs, which would be partially offset by improved logistics, and a reduction in adverse events associated with the current vaccines.

show abstract

Section: Discussionsupporting

confidence: 82%

Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine

Olivera¹,

Grau²,

Dibarboure

et al. 2020

BMC Health Serv Res

View full text Add to dashboard Cite

show abstract

“…The observation that OPV with SIAs incur greater costs than routine IPV immunization is consistent with earlier findings. (85) We emphasize several limitations of the estimates presented in the analysis. We showed the substantial impact of IPV prices potentially changing over time ( Fig.…”

Section: Discussionmentioning

confidence: 99%

The Costs of Future Polio Risk Management Policies

Tebbens¹,

Sangrujee²,

Thompson³

2006

Risk Analysis

View full text Add to dashboard Cite

Decisionmakers need information about the anticipated future costs of maintaining polio eradication as a function of the policy options under consideration. Given the large portfolio of options, we reviewed and synthesized the existing cost data relevant to current policies to provide context for future policies. We model the expected future costs of different strategies for continued vaccination, surveillance, and other costs that require significant potential resource commitments. We estimate the costs of different potential policy portfolios for low-, middle-, and high-income countries to demonstrate the variability in these costs. We estimate that a global transition from routine immunization with oral poliovirus vaccine (OPV) to inactivated poliovirus vaccine (IPV) would increase the costs of managing polio globally, although routine IPV use remains less costly than routine OPV use with supplemental immunization activities. The costs of surveillance and a stockpile, while small compared to routine vaccination costs, represent important expenditures to ensure adequate response to potential outbreaks. The uncertainty and sensitivity analyses highlight important uncertainty in the aggregated costs and demonstrates that the discount rate and uncertainty in price and administration cost of IPV drives the expected incremental cost of routine IPV vs. OPV immunization.

show abstract

“…Desde o ano 2000, tem sido crescente a preocupação com o uso da vacina oral contra a poliomielite, não apenas nos países onde a doença já não mais circula 3,10,11,12,13,14,15,16 , mas também na Índia, onde já existem recomendações para planejar a mudança da OPV para IPV 17,18,19,20 .…”

Section: Isbn: 92-7531619-8unclassified

“…O custo das novas vacinas deve ser avaliado em relação ao custo das doenças para as famílias e a sociedade, mas é importante lembrar que nenhuma análise fár-maco-econômica será favorável à introdução de novas vacinas enquanto houver subnotificação das doenças, seja por falta de recursos diagnósticos ou por falhas no registro dos casos 14 .…”

Section: Isbn: 92-7531619-8unclassified

“…A expectativa de que as novas vacinas terão o mesmo custo das já incorporadas aos programas de vacinação é pouco realista, mas é possível reduzir dramaticamente os custos de produção se houver planejamento para a aquisição de vacinas em grandes quantidades, como se observou após a introdução das vacinas de Hib, hepatite B, rotavírus e hepatite A nos programas de vacinação de diversos países 1,14,22,23,24 .…”

Section: Isbn: 92-7531619-8unclassified

See 1 more Smart Citation

Avances recientes en inmunización

Bricks

2009

Cad. Saúde Pública

View full text Add to dashboard Cite

Polio immunization policy in Mexico: economic assessment of current practice and future alternatives

Cited by 14 publications

References 3 publications

Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine

Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine

The Costs of Future Polio Risk Management Policies

Avances recientes en inmunización

Contact Info

Product

Resources

About